Abstract
ObjectiveExcess weight and related health complications remain under diagnosed and poorly treated in general practice. We aimed to develop and validate a brief screening tool for determining the presence of unknown clinically significant weight-related health complications for potential application in general practice.DesignWe considered 14 self-reported candidate predictors of clinically significant weight-related health complications according to the Edmonton Obesity Staging System (EOSS score of ≥2) and developed models using multivariate logistic regression across training and test data sets. The final model was chosen based on the area under the receiver operating characteristic curve and the Hosmer-Lemeshow statistic; and validated using sensitivity, specificity and positive predictive value.Setting and participantsWe analysed cross-sectional data from the Australian Health Survey 2011–2013 sample aged between 18 and 65 years (n=7518) with at least overweight and obesity.ResultsAn EOSS≥2 classification was present in 78% of the sample. Of 14 candidate risk factors, 6 (family history of diabetes, hypertension, high sugar in blood/urine, high cholesterol and self-reported bodily pain and disability) were automatically included based on definitional or obvious correlational criteria. Three variables were retained in the final multivariate model (age, self-assessed health and history of depression/anxiety). The EOSS-2 Risk Tool (index test) classified 89% of those at ‘extremely high risk’ (≥25 points), 67% of those at ‘very high risk’ (7–24 points) and 42% of those at ‘high risk’ (<7 points) of meeting diagnostic criteria for EOSS≥2 (reference).ConclusionThe EOSS-2 Risk Tool is a simple, safe and accurate screening tool for diagnostic criteria for clinically significant weight-related complications for potential application in general practice. Research to determine the feasibility and applicability of the EOSS-2 Risk Tool for improving weight management approaches in general practice is warranted.
Funder
National Association of Clinical Obesity Services Incorporated
Western Sydney University
iNova Pharmaceuticals (Australia) Pty Ltd
Reference28 articles.
1. The challenge for global health systems in preventing and managing obesity;Wolfenden;Obes Rev,2019
2. PHE 251. Overweight and obesity: an interactive insight AIHW; 2021. https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity-an-interactive-insight/contents/what-is-overweight-and-obesity
3. Comparing the predictive ability of the edmonton obesity staging system with the body mass index for use of health services and pharmacotherapies in Australian adults: a nationally representative cross-sectional study;Atlantis;Clin Obes,2020
4. BOD 12. Impact of overweight and obesity as a risk factor for chronic conditions: Australian burden of disease study. Canberra Australian Institute of Health and Welfare; 2017.
5. Management of overweight and obesity in primary care-a systematic overview of international evidence-based guidelines;Semlitsch;Obes Rev,2019